Gossamer Bio (Gossamer Bio) ROCE %

: -63.48% (As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Gossamer Bio's annualized ROCE % for the quarter that ended in Dec. 2023 was -63.48%.

Gossamer Bio ROCE % Historical Data

The historical data trend for Gossamer Bio's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gossamer Bio Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

-58.61

-51.81

-53.34

-81.78

-68.79

Gossamer Bio Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROCE %																-84.69	-90.75	-97.38	-65.59	-63.48

Gossamer Bio ROCE % Calculation

Gossamer Bio's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-166.306	/	( ( (272.45 - 49.23)	+	(311.916 - 51.598) )	/ 2 )
	=	-166.306	/	( (223.22	+	260.318)	/ 2 )
	=	-166.306	/	241.769
	=	-68.79 %

Gossamer Bio's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	-179.636	/	( ( (347.925 - 42.316)	+	(311.916 - 51.598) )	/ 2 )
	=	-179.636	/	( ( 305.609	+	260.318 )	/ 2 )
	=	-179.636	/	282.9635
	=	-63.48 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

Gossamer Bio (NAS:GOSS) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Gossamer Bio ROCE % Related Terms

Thank you for viewing the detailed overview of Gossamer Bio's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Gossamer Bio (Gossamer Bio) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gossamer Bio Inc (NAS:GOSS) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

4GB:Germany

Address

3013 Science Park Road, Suite 200, San Diego, CA, USA, 92121

Website

https://www.gossamerbio.com

Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.

Executives

Sandra Milligan	director	2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Bryan Giraudo	officer: Chief Financial Officer	7707 GATEWAY BOULEVARD, SUITE 140, NEWARK CA 94560
Richard Aranda	officer: Chief Medical Officer	3013 SCIENCE PARK ROAD, SAN DIEGO CA 92121
Faheem Hasnain	director, officer: Executive Chairman	14 CAMBRIDGE CENTER, CAMBRIDGE MA 02142
Waage Christian	officer: EVP & General Counsel	RECEPTOS, INC., 10835 ROAD TO THE CURE, SUITE 205, SAN DIEGO CA 92121
Caryn Peterson	officer: EVP, Regulatory Affairs	3013 SCIENCE PARK ROAD, SAN DIEGO CA 92121
Laura Carter	officer: Chief Scientific Officer	3013 SCIENCE PARK ROAD, SAN DIEGO CA 92121
Luisa Salter-cid	officer: Chief Scientific Officer	C/O GOSSAMER BIO, INC., 3013 SCIENCE PARK ROAD, SUITE 200, SAN DIEGO CA 92121
Jakob Dupont	officer: Chief Medical Officer	C/O ONCOMED PHARMACEUTICALS, INC., 800 CHESAPEAKE DRIVE, REDWOOD CITY CA 94063
Sheila Gujrathi	director, officer: President & CEO	10835 ROAD TO THE CURE, SUITE 205, SAN DIEGO CA 92121
Omega Fund V Gp, L.p.	10 percent owner	888 BOYLSTON ST., SUITE 1111, BOSTON MA 02199
Omega Fund V Gp Manager, Ltd.	10 percent owner	888 BOYLSTON ST., SUITE 1111, BOSTON MA 02199
Omega Fund V, L.p.	10 percent owner	888 BOYLSTON ST., SUITE 1111, BOSTON MA 02199
Otello Stampacchia	director, 10 percent owner	888 BOYLSTON ST., SUITE 1111, BOSTON MA 02199
Russell J. Cox	director	C/O JAZZ PHARMACEUTICALS, PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2